Return on Equity: The amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested. Calculated as: Income from Continuing Operations / Total Common Equity
Telomir Pharmaceuticals, Inc. (TELO) had Return on Equity of -34.20% for the most recently reported fiscal quarter, ending 2026-06-30.
| Income Statement Financials | |
-- |
|
$-47.84M |
|
-- |
|
-- |
|
$1.76M |
|
$-1.76M |
|
$0.04M |
|
$-1.72M |
|
$-1.72M |
|
$-1.72M |
|
$-1.72M |
|
$-1.72M |
|
$-1.72M |
|
$-1.76M |
|
$-1.76M |
|
60.84M |
|
60.84M |
|
$-0.79 |
|
$-0.79 |
|
| Balance Sheet Financials | |
$5.37M |
|
-- |
|
-- |
|
$5.37M |
|
$0.33M |
|
-- |
|
-- |
|
$0.33M |
|
$5.03M |
|
$5.03M |
|
$5.03M |
|
68.78M |
|
| Cash Flow Statement Financials | |
$-2.79M |
|
-- |
|
$0.67M |
|
$7.29M |
|
$5.17M |
|
$-2.12M |
|
$0.83M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
16.14 |
|
-- |
|
-- |
|
-- |
|
0.03 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-2.79M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
|
Return on Equity |
-34.20% |
-34.20% |
|
-32.08% |
|
-34.20% |
|
$0.07 |
|
$-0.05 |
|
$-0.05 |
|